Asensus Surgical (NYSEAMERICAN:ASXC) Given “Overweight” Rating at Cantor Fitzgerald
Asensus Surgical (NYSEAMERICAN:ASXC – Get Free Report)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a research report issued on Tuesday, Benzinga reports. They currently have a $1.00 price target on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 241.41% from the company’s current price. Separately, HC Wainwright restated a “buy” rating and set a $2.00 price target on shares of Asensus Surgical in a report on Friday, August 11th.
Get Asensus Surgical alerts: Get Our Latest Research Report on ASXC Asensus Surgical Price Performance Institutional Inflows and Outflows ASXC stock opened at $0.29 on Tuesday. Asensus Surgical has a 12-month low of $0.27 and a 12-month high of $1.18. The company has a market capitalization of $77.29 million, a price-to-earnings ratio of -0.86 and a beta of 1.60. Hedge funds and other institutional investors have recently modified their holdings of the business.
Masters Capital Management LLC grew its stake in Asensus Surgical by 8.5% in the 2nd quarter. Masters Capital Management LLC now owns 2,000,000 shares of the company’s stock valued at $1,010,000 after buying an additional 157,000 shares during the last quarter. BlackRock Inc. grew its stake in Asensus Surgical by 1.2% in the 2nd quarter. BlackRock Inc. now owns 3,699,987 shares of the company’s stock valued at $1,868,000 after buying an additional 44,503 shares during the last quarter.
Lazari Capital Management Inc. acquired a new position in Asensus Surgical in the 2nd quarter valued at $35,000. JPMorgan Chase & Co. acquired a new position in Asensus Surgical in the 1st quarter valued at $31,000. Finally, State Street Corp grew its stake in Asensus Surgical by 17.1% in the 1st quarter. State Street Corp now owns 957,129 shares of the company’s stock valued at $630,000 after buying an additional 140,000 shares during the last quarter. Institutional investors own 11.04% of the company’s stock.
Asensus Surgical Company Profile (Get Free Report) Asensus Surgical, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery.
Read More Receive News & Ratings for Asensus Surgical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Asensus Surgical and related companies with MarketBeat. com’s FREE daily email newsletter.
